Average Price Target: $18.00
▲ +122.22% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Co-Diagnostics in the last 3 months. The average price target is $18.00, with a high forecast of $20.00 and a low forecast of $16.00. The average price target represents a 122.22% upside from the last price of $8.10.
The current consensus among 2 investment analysts is to buy stock in Co-Diagnostics. This Buy consensus rating has held steady for over two years.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.